Medical News

RSS

MedImmune announces in-licensing agreement with Amgen for IL-1 pathway targeting novel monoclonal antibody

MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases.

7 Jan 2011

CORE Health Centers is now Inspire Health

On January 7th CORE Health Centers, LLC: a distinguished outpatient, multi-disciplinary, weight management treatment center in the Chicago area, officially changed its name to Inspire Health. The change to Inspire Health more accurately reflects its mission of providing effective psychological and physiological treatments for healthy weight loss and management.

7 Jan 2011

Scientists identify type of cell at the origin of brain tumors

Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas, which are a type of glioma - a category that defines the most common type of malignant brain tumor.

7 Jan 2011

Texas Attorney General does not oppose Baylor-Select joint venture

Baylor Health Care System ("Baylor") and Select Medical Corporation ("Select") today announced that they have received notification from the Office of the Attorney General of the State of Texas that it has completed its review of the proposed joint venture between affiliates of Baylor and Select and does not oppose the joint venture.

7 Jan 2011

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.

7 Jan 2011

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Iroko Pharmaceuticals, LLC today reported the results of the Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using proprietary, patent protected nanotechnology.

7 Jan 2011

Majority of U.S. adults strongly support innovative programs to discourage teen pregnancy

Every hour in the United States, about 40 children are born to teenage mothers. Americans consistently rate teen pregnancy as one of the top 10 biggest health problems for young people and the U.S. still has the highest teen birth rate among all industrialized countries -- despite decreases in the birth rate during the past 20 years.

7 Jan 2011

Babies' brains process language the same way as adults

Babies, even those too young to talk, can understand many of the words that adults are saying - and their brains process them in a grown-up way.

7 Jan 2011

Impulse Monitoring announces acquisition of Great Lakes Intraoperative Monitoring

Impulse Monitoring, Inc. (IMI), a leading provider of intraoperative neurophysiologic monitoring (IONM) services to hospitals, today announced that it has acquired the assets of Great Lakes Intraoperative Monitoring, LP (GLIM), a subsidiary of Williamsville, NY-based Archer Medical Diagnostic Testing, Inc.

7 Jan 2011

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

Unexpected discovery holds promise for PTSD, other anxiety disorders

An unexpected discovery by UCLA life scientists holds promise for the future development of treatments for post-traumatic stress disorder and other anxiety disorders, and potentially for Alzheimer's disease and other memory-impairment diseases.

7 Jan 2011

ADA commends HHS for reaffirming safety, efficacy of optimal community water fluoridation

The American Dental Association (ADA) today commended the Federal agencies responsible for public health and safety for recalibrating the ratio of fluoride to water that they consider optimal based on scientific evaluation and the full appreciation of fluoride received from all sources.

7 Jan 2011

Underwriters exercise over-allotment option in Amarin ADS public offering

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), the underwriters of the offering have exercised in full their option to purchase up to an aggregate of 1,800,000 additional ADSs to cover over-allotments.

7 Jan 2011

Sutro, Pfizer enter multi-year collaboration for novel peptide-based therapeutics

Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.

7 Jan 2011

Radiosurgery may bring improvement for patients with extremely severe -compulsive disorder

For patients with extremely severe -compulsive disorder (OCD), a procedure called radiosurgery may bring improvement when other treatments have failed, according to a study in the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

7 Jan 2011

Aratana closes $20 million Series A financing

Aratana Therapeutics, a newly-formed company focused on the development of innovative therapies for the animal health industry, today announced that it has closed a $20 million Series A financing led by MPM Capital and Avalon Ventures.

7 Jan 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

7 Jan 2011

MMRF awards $3 million under 2010 Biotech Investment Awards program

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

7 Jan 2011

Low incentive fails to 'switch off' brain regions involved in mind-wandering among ADHD children

Brain scans of children with attention-deficit/hyperactivity disorder (ADHD) have shown for the first time why people affected by the condition sometimes have difficulty in concentrating. The study, by experts at The University of Nottingham, may explain why parents often say that their child can maintain concentration when they are doing something that interests them, but struggles with boring tasks.

7 Jan 2011

Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.

7 Jan 2011

Medical News

MedImmune announces in-licensing agreement with Amgen for IL-1 pathway targeting novel monoclonal antibody

CORE Health Centers is now Inspire Health

Scientists identify type of cell at the origin of brain tumors

Texas Attorney General does not oppose Baylor-Select joint venture

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Majority of U.S. adults strongly support innovative programs to discourage teen pregnancy

Babies' brains process language the same way as adults

Impulse Monitoring announces acquisition of Great Lakes Intraoperative Monitoring

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

Unexpected discovery holds promise for PTSD, other anxiety disorders

ADA commends HHS for reaffirming safety, efficacy of optimal community water fluoridation

Underwriters exercise over-allotment option in Amarin ADS public offering

Sutro, Pfizer enter multi-year collaboration for novel peptide-based therapeutics

Radiosurgery may bring improvement for patients with extremely severe -compulsive disorder

Aratana closes $20 million Series A financing

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

MMRF awards $3 million under 2010 Biotech Investment Awards program

Low incentive fails to 'switch off' brain regions involved in mind-wandering among ADHD children

Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News